Literature DB >> 27906636

Urat1-Uox double knockout mice are experimental animal models of renal hypouricemia and exercise-induced acute kidney injury.

Makoto Hosoyamada1, Yu Tsurumi2, Hidenori Hirano2, Naoko H Tomioka1, Yuko Sekine2, Takayuki Morisaki3, Shunya Uchida4.   

Abstract

Renal hypouricemia (RHUC) is a hereditary disease characterized by a low level of plasma urate but with normal urinary urate excretion. RHUC type 1 is caused by mutations of the urate transporter URAT1 gene (SLC22A12). However, the plasma urate levels of URAT1 knockout mice are no different from those of wild-type mice. In the present study, a double knockout mouse, in which the URAT1 and uricase (Uox) genes were deleted (Urat1-Uox-DKO), were used as an experimental animal model of RHUC type 1 to investigate RHUC and excise-induced acute kidney injury (EIAKI). Mice were given a variable content of allopurinol for one week followed by HPLC measurement of urate and creatinine concentrations in spot urine and blood from the tail. The urinary excretion of urate in Urat1-Uox-DKO mice was approximately 25 times higher than those of humans. With allopurinol, the plasma urate levels of Urat1-Uox-DKO mice were lower than those of Uox-KO mice. There were no differences in the urinary urate excretions between Urat1-Uox-DKO and Uox-KO mice administered with 9 mg allopurinol /100 g feed. In the absence of allopurinol, plasma creatinine levels of some Urat1-Uox-DKO mice were higher than those of Uox-KO mice. Consequently, hypouricemia and normouricosuria may indicate that the Urat1-Uox-DKO mouse administered with allopurinol may represent a suitable animal model of RHUC type 1. Urat1-Uox-DKO mice without allopurinol exhibited acute kidney injury, thus providing additional benefit as a potential animal model for EIAKI. Finally, our data indicate that allopurinol appears to provide prophylactic effects for EIAKI.

Entities:  

Keywords:  Renal hypouricemia; allopurinol; animal models; urate transporter; uricase

Mesh:

Substances:

Year:  2016        PMID: 27906636     DOI: 10.1080/15257770.2016.1143559

Source DB:  PubMed          Journal:  Nucleosides Nucleotides Nucleic Acids        ISSN: 1525-7770            Impact factor:   1.381


  11 in total

1.  Xanthine Oxidoreductase Inhibitors Suppress the Onset of Exercise-Induced AKI in High HPRT Activity Urat1-Uox Double Knockout Mice.

Authors:  Takuji Hosoya; Shunya Uchida; Shigeru Shibata; Naoko H Tomioka; Koji Matsumoto; Makoto Hosoyamada
Journal:  J Am Soc Nephrol       Date:  2021-11-19       Impact factor: 10.121

2.  Emerging Roles of the Human Solute Carrier 22 Family.

Authors:  Sook Wah Yee; Kathleen M Giacomini
Journal:  Drug Metab Dispos       Date:  2021-12-17       Impact factor: 3.579

3.  Differential gene expression of ABCG2, SLC22A12, IL-1β, and ALPK1 in peripheral blood leukocytes of primary gout patients with hyperuricemia and their comorbidities: a case-control study.

Authors:  Paniagua-Díaz Natsuko; Sanchez-Chapul Laura; Clavijo-Cornejo Denise; Ventura-Ríos Lucio; Aguilar-Salinas Carlos; Sanchez-Muñoz Fausto; López-Macay Ambar
Journal:  Eur J Med Res       Date:  2022-05-03       Impact factor: 4.981

4.  Perfecting a high hypoxanthine phosphoribosyltransferase activity-uricase KO mice to test the effects of purine- and non-purine-type xanthine dehydrogenase (XDH) inhibitors.

Authors:  Takuji Hosoya; Shunya Uchida; Shigeru Shibata; Naoko H Tomioka; Makoto Hosoyamada
Journal:  Br J Pharmacol       Date:  2020-02-18       Impact factor: 8.739

5.  Shortage of Cellular ATP as a Cause of Diseases and Strategies to Enhance ATP.

Authors:  Todd A Johnson; H A Jinnah; Naoyuki Kamatani
Journal:  Front Pharmacol       Date:  2019-02-19       Impact factor: 5.810

6.  Hyperuricemia causes kidney damage by promoting autophagy and NLRP3-mediated inflammation in rats with urate oxidase deficiency.

Authors:  Mian Wu; Yiwen Ma; Xiaoting Chen; Nan Liang; Shen Qu; Haibing Chen
Journal:  Dis Model Mech       Date:  2021-03-24       Impact factor: 5.758

Review 7.  Role of ATP-Small Heat Shock Protein Interaction in Human Diseases.

Authors:  Sandip K Nandi; Alok Kumar Panda; Ayon Chakraborty; Shivani Rathee; Ipsita Roy; Subhashree Barik; Saswati Soumya Mohapatra; Ashis Biswas
Journal:  Front Mol Biosci       Date:  2022-02-16

8.  OAT10/SLC22A13 Acts as a Renal Urate Re-Absorber: Clinico-Genetic and Functional Analyses With Pharmacological Impacts.

Authors:  Yu Toyoda; Yusuke Kawamura; Akiyoshi Nakayama; Keito Morimoto; Seiko Shimizu; Yuki Tanahashi; Takashi Tamura; Takaaki Kondo; Yasufumi Kato; Kimiyoshi Ichida; Hiroshi Suzuki; Nariyoshi Shinomiya; Yasushi Kobayashi; Tappei Takada; Hirotaka Matsuo
Journal:  Front Pharmacol       Date:  2022-04-06       Impact factor: 5.988

9.  Lesinurad: what the nephrologist should know.

Authors:  Maria Dolores Sanchez-Niño; Binbin Zheng-Lin; Lara Valiño-Rivas; Ana Belen Sanz; Adrian Mario Ramos; Jose Luño; Marian Goicoechea; Alberto Ortiz
Journal:  Clin Kidney J       Date:  2017-05-26

10.  SLC2A9 (GLUT9) mediates urate reabsorption in the mouse kidney.

Authors:  Muriel Auberson; Sophie Stadelmann; Candice Stoudmann; Klaus Seuwen; Robert Koesters; Bernard Thorens; Olivier Bonny
Journal:  Pflugers Arch       Date:  2018-08-13       Impact factor: 3.657

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.